Anxiety about having an allergic reaction was the most commonly reported issue
Highest rates seen during COVID-19 pandemic versus before pandemic and in females, those aged 14 to 17 and 18 to 22 years
Small, but significant effects seen at six months and sustained at 12 months
No increase observed in diagnoses following onset of COVID-19, but increase seen in proportion of women filling benzodiazepine prescription
Patients with CRS have increased risk for developing common psychiatric disorders and vice versa
Engagement and quality ratings were similar across incentive conditions
Single 20-minute session had significant efficacy for reducing pain intensity, pain unpleasantness, anxiety
Associations seen for chronic and new-onset anxiety, but not for resolved anxiety, with all-cause dementia risk